Through network pharmacology analysis, researchers predicted the potential active compounds and targets in the Hengqing II formula for treating AD, exerting anti-inflammatory, antioxidant, and neuroprotective effects mainly by regulating signaling pathways such as PI3K-Akt, NF-κB, and MAPK45. This evidence concerns the gene NFKB1 and Alzheimer disease.